The migraine therapeutics market in EU5 countries will increase at a compounded annual growth rate of 0.2% between 2010 and 2018. This reserved market growth is largely attributed to the generic erosion of leading migraine therapies. Migraine therapeutics market in the US, Germany, France, UK, Spain, Italy, and Japan will earn revenues of $4.5 billion by 2018, increasing at a compounded annual growth rate of 2.7% between 2010 and 2018.

Merck & Co's Telcagepant is poised to be the next market leader to drive the migraine therapeutics market in EU5 countries. Telcagepant will gain wider acceptance among the patient and physician population resulting in greater use. Key opinion leaders are enthusiastic about the expected launch and contribution of Telcagepant to the significant growth of migraine therapeutics market. Also, the need for better efficacious medication will drive the uptake of these therapies.

The US will remain the largest market in 2018 with 79% market share. The market will benefit from favorable population demographics. Pharmaceutical companies should center their attention towards research and development activities, and sustaining their product's market share.

Report overview

The new report from Commercial Insights, ‘Migraine Therapeutics Market in Europe: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis' provide in-depth analysis of the current and future migraine market landscape in EU5 countries. The report covers all aspects of the migraine therapeutics market for the Germany, France, UK, Spain, and Italy. It includes migraine market forecasts, patient flow, epidemiology analysis, diagnosis rate analysis, treatment rate analysis, patient forecast, current competition, future competitive landscape, unmet need, and pipeline analysis. The report also provides insights in to the market events that impact the migraine therapeutics market by geography, and detailed clinical insights of high potential migraine therapies in the pipeline.

Scope of the Report

• Geographies Covered: Global, Germany, France, UK, Spain, and Italy
• Forecast Period: 8 Years (2010 to 2018)

Key Features of the Report

Market Analysis

• Migraine therapeutics market size and forecast by geography
• Insights in to market events that impact the migraine therapeutics market by geography
• Leading therapies by geography

Competitive Landscape Analysis

• Market share insights of leading brands in the migraine therapeutics market
• Future market share analysis of the global migraine therapeutics market
• Profiles of leading brands by their market shares

Patient Flow Analysis

• Patient flow study with diagnosis rate and treated population rate by geography
• Analysis and forecasts of migraine prevalence population by geography
• Analysis and forecasts of migraine diagnosis population by geography
• Analysis and forecasts of migraine treated population by geography

Unmet Need

• Unmet need analysis of the global migraine therapeutics market

Pipeline Analysis

• Analysis of migraine pipeline molecules by phase of development
• Detailed clinical profiles of high potential phase 3 molecules